Facebook Instagram Pinterest Reddit Tumblr Twitter Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 132

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #219: Trump Admin. Vetoed Compass Priority Voucher; Ibogaine in Focus; Definium Sued by Former Vendor; Psychedelics Feature in Epstein Files

Center for MINDS: Bruce Damer on Why We Need Psychedelic-Catalysed Innovation

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

Psychedelics Weekly – Genetic Memory, “The Psychedelic Renaissance,” and Harm Reduction...

Webinar: Psychedelic Integration and Depth Relational Process

Abuse Potential: Considerations for Rescheduling MDMA and Psychedelics

PT376 – Ketamine and Psychedelic-Assisted Therapy as Employee Benefits

Psychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies...

Psychedelic Research Bulletin: November 2022

Psychedelics Weekly – Cannabis as an Adjunct Cancer Treatment & 5-MeO-DMT...

Numinus Wellness Inc. Reports Q4 2022 and Annual Results

PsyBio Therapeutics Announces Non-Brokered Private Placement Financing

FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES

1...131132133...307Page 132 of 307

EDITOR PICKS

Pα+ Psychedelic Bulletin #219: Trump Admin. Vetoed Compass Priority Voucher; Ibogaine...

Center for MINDS: Bruce Damer on Why We Need Psychedelic-Catalysed Innovation

The Psychedelic News Feed: January 26 – Febraury 1, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr Twitter Youtube
    ©